Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2

An Overview of the Adaptive Designs Accelerating Promising Trials Into Treatments (ADAPT-IT) Project

(2012) William J. Meurer et al.   ANNALS OF EMERGENCY MEDICINE

Reports from the 2010 Clinical and Translational Cancer Research Think Tank Meeting: Design Strategies for Personalized Therapy Trials

(2012) D. A. Berry et al.   CLINICAL CANCER RESEARCH

Worth Adapting? Revisiting the Usefulness of Outcome-Adaptive Randomization

(2012) J. J. Lee et al.   CLINICAL CANCER RESEARCH

The impact of enrollment in clinical trials on survival of patients with glioblastoma

(2012) Tal Shahar et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Bayesian Adaptive Randomized Trial Design for Patients With Recurrent Glioblastoma

(2012) Lorenzo Trippa et al.   JOURNAL OF CLINICAL ONCOLOGY

Pathologic Complete Response Predicts Recurrence-Free Survival More Effectively by Cancer Subset: Results From the I-SPY 1 TRIAL—CALGB 150007/150012, ACRIN 6657

(2012) Laura J. Esserman et al.   JOURNAL OF CLINICAL ONCOLOGY

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

(2012) Wolfgang Wick et al.   LANCET ONCOLOGY

Phase 2 trial design in neuro-oncology revisited: a report from the RANO group

(2012) Evanthia Galanis et al.   LANCET ONCOLOGY

Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival

(2012) L. S. Hu et al.   NEURO-ONCOLOGY

Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)

(2011) Laura J. Esserman et al.   BREAST CANCER RESEARCH AND TREATMENT

Role of isocitrate dehydrogenase in glioma

(2011) Brian M Alexander et al.   Expert Review of Neurotherapeutics

Adaptive clinical trials in oncology

(2011) Donald A. Berry   Nature Reviews Clinical Oncology

Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide

(2011) M.-Y. C. Polley et al.   NEURO-ONCOLOGY

A multigene predictor of outcome in glioblastoma

(2011) H. Colman et al.   NEURO-ONCOLOGY

The BATTLE Trial: Personalizing Therapy for Lung Cancer

(2011) Edward S. Kim et al.   Cancer Discovery

Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas

(2010) Christian Hartmann et al.   ACTA NEUROPATHOLOGICA

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

(2010) Roel G.W. Verhaak et al.   CANCER CELL

Survival of Patients with Newly Diagnosed Glioblastoma Treated with Radiation and Temozolomide in Research Studies in the United States

(2010) S. A. Grossman et al.   CLINICAL CANCER RESEARCH

The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee

(2010) L. Seymour et al.   CLINICAL CANCER RESEARCH

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Adaptive Clinical Trials: The Promise and the Caution

(2010) Donald A. Berry   JOURNAL OF CLINICAL ONCOLOGY

Incorporation of Biomarker Assessment in Novel Clinical Trial Designs: Personalizing Brain Tumor Treatments

(2010) Evanthia Galanis et al.   Current Oncology Reports

I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy

(2009) AD Barker et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients

(2009) Amy B Heimberger et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

MGMTPromoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients

(2008) Alba A. Brandes et al.   JOURNAL OF CLINICAL ONCOLOGY

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

(2008) Roger McLendon et al.   NATURE

Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas

(2008) Kathleen R. Lamborn et al.   NEURO-ONCOLOGY

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE